Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and new therapies are needed. RG7787 is a novel low-immunogenic anti-mesothelin recombinant immunotoxin (RIT), engineered to overcome the limitations of SS1P, a RIT now in clinical trials. In vitro activity was evaluated on five established PDAC cell lines (KLM-1, AsPC-1, BxPC-3, Panc 3.014 and PK-1) and on PDAC cells directly established from a patient tumor (GUMC108). RG7787 had subnanomolar IC50s in most cell lines, and was significantly more active than SS1P in GUMC108, KLM-1 and Panc 3.014 cells. GUMC108 was most sensitive, with RG7787 killing >99% of the cells. In a subcutaneous KLM-1 xenograft mouse model, two cycles of 3 x 2.5 mg/kg RG7787 QOD combined with two cycles of 1 x 50 mg/kg paclitaxel induced nearcomplete responses, with all tumors regressing below 5 mm 3 within 30 days after therapy was initiated (>95% decrease) and no significant growth increase for at least another 3 weeks. RG7787 alone gave limited but significant regressions and paclitaxel by itself arrested tumor growth. Quantifying the uptake of Alexa647-labeled RG7787 in tumors showed that the RIT reached only 45% of KLM-1 cells, accounting in part for the limited responses. Paclitaxel did not improve RG7787 uptake, which thus cannot explain the beneficial effect of the combination therapy. In conclusion, RG7787 has high cytotoxic activity on PDAC cell lines as well as on primary patient cells. In vivo, this novel RIT gives durable near-complete tumor responses when combined with paclitaxel. RG7787 merits further evaluation for the treatment of PDAC.
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer death in the US (1) . The most common subtype, pancreatic ductal adenocarcinoma (PDAC), is notoriously resistant to most chemotherapeutic agents, and alternative treatment options are urgently needed.
Mesothelin is a 40-kDa cell surface glycoprotein (2) that is uniformly and highly expressed in virtually all PDAC and several other malignancies, including mesothelioma (3, 4) . Because mesothelin is not expressed on normal essential organs, it is an established target to direct therapies against (5, 6) . Our laboratory produces and evaluates recombinant immunotoxins (RITs) for cancer treatment. Current RITs in clinical trials are composed of an antigen-binding Fv fused to a 38-kDa portion of Pseudomonas exotoxin A (PE) (7) . The Fv binds to the cancer cells, after which the RIT is internalized via receptor-mediated endocytosis, and traffics via the endocytic compartment and Golgi to the endoplasmic reticulum. During this process the toxin gets separated from the Fv by the action of furin. PE is subsequently transferred to the cytosol, where it ADP-ribosylates and inactivates elongation factor-2. This halts protein synthesis and leads to programmed cell death (8) .
We have been evaluating the activity of the anti-mesothelin SS1P and anti-CD22 Moxetumomab pasudotox (MP) RITs in the clinic. In a phase I trial, MP produced durable complete remissions in 46% of patients with refractory hairy cell leukemia (9) and a phase 3 trial is now open (ClinicalTrials.gov Identifier: NCT01829711). In phase I clinical trials in patients with solid tumors, SS1P was well-tolerated but the high immunogenicity of the PE portion typically induced neutralizing anti-drug antibodies after one treatment cycle, resulting in limited antitumor activity (10,11). Our laboratory has focused on reducing this dose-limiting immunogenicity. One approach aims at suppressing the host immune system, by combining SS1P with immune-depleting chemotherapeutic agents. In a recent phase I trial (ClinicalTrials.gov Identifier: NCT01362790), this allowed for multiple SS1P cycles which resulted in striking and unprecedented responses in patients with advanced refractory mesothelioma (12) . These findings clearly illustrate that RITs can have high anti-tumor efficacy in malignancies with a poor prognosis. A second approach aims at minimizing PE immunogenicity via re-engineering RITs. By removing B-cell epitopes and protease-sensitive regions of PE38, a truncated de-immunized 24-kDa PE fragment (PE24) has been developed. PE24 variants have less reactivity with human anti-sera, are resistant to lysosomal degradation, and display a decreased non-specific toxicity in rodent models in vivo (13) (14) (15) . In collaboration with Roche Innovation Center Penzberg, Germany, this lowimmunogenic PE24 backbone has been integrated into a novel anti-mesothelin RIT by linking it to a humanized anti-mesothelin Fab (huSS1), thereby increasing size and circulatory half-life.
This clinically-optimized RIT is named RG7787 (Figure 1 ) and is being rapidly developed for evaluation in patients.
SS1P is highly cytotoxic to cells obtained from patients with ovarian cancer and mesothelioma (6) , but has limited activity in mesothelin-expressing PDAC cell lines (16, 17) . Consequently, anti-mesothelin RITs were not yet evaluated in PDAC xenograft models. The aims of the current study were a) to evaluate the cytotoxicity of RG7787 in established and primary PDAC cell lines, b) to evaluate the anti-tumor activity of RG7787 in a PDAC mouse model, both alone and in combination with paclitaxel, and c) to quantify the percentage of PDAC cells in vivo that are reached by RG7787 and link this uptake to response. protease-sensitive regions and B-cell epitopes (13, 15) . In addition, seven mutations in domain III (R505A, R427A, R490A, R467A, D463A, R458A, and R538A) were introduced to silence previously identified B-cell epitopes (14) . Pharmacy, Bethesda, MD). RPMI-1640 was supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen). Cell line identities were verified using short tandem repeat analysis in August 2012 (NCI, Frederick, MD).
MATERIALS AND METHODS

Recombinant immunotoxins
Clinical
GUMC108 is a primary PDAC cell line, directly derived from a patient tumor as previously described (19) , and was a gift from Prof. Richard Schlegel in July 2012 (Georgetown University Medical Center, DC). GUMC108 cells were cultivated on irradiated (3000 rad) Swiss 3T3 fibroblasts (J2 strain) in F medium Differential trypsinization was used to separate feeder and epithelial cells during passaging. In short-term cell-based assays, GUMC108 cells were cultured without the irradiated fibroblasts, to avoid interference from the feeder layer. All cells were maintained at 37°C in a humidified incubator, with 5% CO 2 . 
In vivo RG7787 uptake in tumors
The cellular uptake of RG7787 within subcutaneous KLM-1 tumors was quantified by modifying a previously established method (21) . In brief, animals were sacrificed, tumors were harvested 
RESULTS
Mesothelin surface expression of PDAC cell lines
Mesothelin surface expression was evaluated by flow cytometry in five established PDAC cell lines and one cell line (GUMC108) directly derived from a patient PDAC tumor. Panc 3.014, KLM-1, GUMC108, and AsPC-1 had high mesothelin expression (30,000 to 90,000 sites per cell), whereas PK-1 and BxPC-3 had low expression (3000 to 5000 sites per cell) ( Table 1 ).
In vitro cytotoxic activity of RG7787 versus SS1P
Cell growth inhibition: PDAC cell lines were treated for 72 hrs with SS1P or RG7787 and cell viability was evaluated by ATP measurements. To account for the differences in molecular weight between SS1P (62 kDa) and RG7787 (73 kDa), IC 50 s are presented in ng/ml and pM (Table 1) . RG7787 had subnanomolar IC50s in most cell lines, and was significantly more active than SS1P in three out of six cell lines: Panc 3.014 (p = 0.008), KLM-1 (p < 0.0001), and GUMC108 (p = 0.0005). SS1P and RG7787 did not significantly differ in AsPC-1 (p = 0.15) or BxPC-3 (p = 0.53). In PK-1, RG7787 did not reach an IC50 below 1 μg/ml (Table 1 ). SS1P and RG7787 showed the highest activity in the primary cell line GUMC108 and the established cell line KLM-1 (Figure 2A ).
Cell death: ATP assays cannot differentiate between cell proliferation arrest and cell death (22) .
We evaluated cell death in the two most sensitive cell lines, KLM-1 and GUMC108, by brightfield microscopy and counting viable cells. Cells were incubated for 72 hrs with 100 ng/ml SS1P or 117 ng/ml RG7787 (the molar equivalent of 100 ng/ml SS1P). Photomicrographs of KLM-1 and GUMC108 cells at day 1 (just before adding the RITs), day 2 and day 4 (72 hr incubation) confirmed that RG7787 was more effective in killing cells than SS1P (Figure 2C-D 2B ). RG7787 in KLM-1 and both treatments in GUMC108 gave fewer cells remaining on day 4 than were counted on day 1. These data confirm that the RITs kill cells, and not just inhibit growth.
In vitro uptake of RG7787 and SS1P
An early step in RIT action is its binding and internalization. To evaluate whether the difference in activity between SS1P and RG7787 was due to higher cellular uptake of RG7787, we measured the in vitro internalization of both Alexa-647-labeled RITs in KLM-1 cells at 30, 60 and 120 min. Flow analysis showed that the uptake of SS1P and RG7787 was similar at the three time points ( Figure 3A) . The enhanced activity of RG7787 is thus not due to increased uptake, but some other event.
Inhibition of protein synthesis by RG7787 and SS1P
A later step in RIT action that is essential for cell killing is protein synthesis arrest due to the inactivation of elongation factor 2. To evaluate whether the enhanced RG7787 activity could be detected at the level of protein synthesis inhibition, KLM-1 and GUMC108 cells were incubated with 100 ng/ml SS1P and 117 ng/ml RG7787 for 16 hrs (Figure 3B ), after which [ 
with the higher sensitivity of GUMC108, protein synthesis was significantly more inhibited by SS1P (p < 0.0001) and RG7787 (p = 0.01), compared to KLM-1. This indicates that the improved activity of RG7787 is related to events occurring prior to the protein synthesis inhibition step.
In vivo activity of RG7787 in a KLM-1 xenograft KLM-1 cells were grown as a subcutaneous xenograft in athymic nude mice. We first evaluated SS1P at MTD; 3 x 0.4 mg/kg SS1P QOD iv (n=3) showed no anti-tumor response compared to control mice (n=3) ( Figure 4A ). In contrast, animals treated iv with 3 x 2.5 mg/kg RG7787 QOD (n=6) showed a significant decrease in tumor size on day 5, from two days after the second dose on (-13%, p = 0.008) ( Figure 4B) . A second cycle of 3 x 2.5 mg/kg RG7787 QOD was initiated 5 days after the third RG7787 dose, when the tumors started to regrow. These three additional doses, however, did not induce additional tumor response. To try to improve the anti-tumor response, we combined RG7787 with paclitaxel. The combination of RITs with chemotherapeutics has previously shown to benefit tumor response (21, (23) (24) (25) . One day prior to the start of a first 3 x RG7787 cycle, 50 mg/kg paclitaxel was administrated ip. The combination of paclitaxel and RG7787 gave a significant tumor regression, which increased with a second treatment cycle of paclitaxel and 3 x RG7787. On day 26, 12 days after the last dose of RG7787, all six tumors had regressed below 5 mm Table S1 ).
IHC evaluation of KLM-1 tumors
To evaluate the effect of treatment on tumor histology, untreated and treated KLM-1 tumors were harvested at different time points, and stained with H&E and cleaved caspase 3 ( Figure 5 ).
In an untreated tumor, KLM-1 cells were organized in clusters surrounded by connective tissue and limited apoptosis was detected, as indicated by the lack of cleaved caspase 3 staining ( Figure   5A ). The effect of paclitaxel was evaluated by harvesting a tumor 1 day after a 50 mg/kg injection (1d+), the standard time point at which RG7787 is administrated in the combination group. Paclitaxel disrupted tumor organization and induced apoptosis (5A). We also evaluated the effect of two treatment cycles of 50 mg/kg paclitaxel and/or 3 x 2.5 mg/kg RG7787 QOD ( Figure 5B ). Tumors were harvested at 17 and 24 days after the last dose of RG7787 and paclitaxel, respectively. In tumors treated with RG7787 or paclitaxel alone, the effect of treatment was obvious with a disrupted organization and empty spaces present within the tumor.
In the tumor treated with two cycles of the combination, the effect was striking. There was an Figure S2) .
RG7787 uptake in KLM-1 tumors
To evaluate how many of the tumor cells take up RG7787 in vivo, we optimized a previously developed method (21) for use in KLM-1 tumors. Briefly, after injection of Alexa-647-labeled RG7787, the tumor is dissociated and the percentage of Alexa-647 positive tumor cells is quantified with flow cytometry. To determine maximal uptake, mice were injected iv with 2.5 mg/kg RG7787-Alexa647, and tumors were harvested at times ranging from 5 min to 14 hrs after injection. The number of KLM-1 cells that internalized RG7787 increased over time, with a highest uptake of 45% at 6 hrs ( Figure 4C ). This indicates that the RG7787 dose we treat mice with reaches only about half of the tumor cells, which in part can explain the limited tumor response of RG7787 as a single therapy. We previously found that paclitaxel treatment of mice with A431/H9 tumors increased the uptake of SS1P into the cells within the tumor (21) . To determine if paclitaxel treatment did the same for RG7787 in KLM-1 tumors, we evaluated uptake after administration of 2.5 mg/kg RG7787-Alexa647, alone or preceded by 50 mg/kg paclitaxel one or three days earlier. Paclitaxel had no effect on RG7787 uptake ( Figure 4D ). 
DISCUSSION
Our goal is to develop a new treatment for pancreatic cancer. We report here that RG7787 has high cytotoxic activity against mesothelin-expressing PDAC cells in vitro, and in combination with paclitaxel causes profound and durable tumor regressions in mice. RG7787 is a novel RIT designed to have low immunogenicity and fewer side-effects than SS1P, with the latter recently reported to have high activity in advanced mesothelioma patients (12) . (26), we also studied PDAC cells directly derived from a patient tumor, GUMC108. These cells were grown using an approach that maintains the phenotype of the primary tumor, allowing for, e.g., in vitro chemo-sensitivity testing of patient cells (19, 27) . We found that RG7787 had subnanomolar IC 50 s in most cell lines, and was most active on GUMC108 cells.
Enhanced activity of RG7787 versus SS1P is cell-line specific
RG778 had a significantly enhanced activity compared to SS1P in half of the PDAC cell lines.
The ability to inhibit protein synthesis correlated with the cytotoxic activity of SS1P and RG7787, suggesting that the mechanism for the improved activity of RG7787 lies upstream of the protein synthesis inhibition. We found no difference in in vitro uptake between SS1P and RG7787 in KLM-1 cells. The higher activity of RG7787 may be attributable to the deletion of protease-sensitive regions in PE domain II, which makes it resistant to degradation in the endolysosomal system, a potential barrier to effective RIT treatment (28, 29) . It remains unclear, however, why the improvement in activity was not observed in all probed cell lines. Further research is needed to elucidate these cell-specific differences. 
RG7787 has significant tumor response and moderate uptake in vivo
We evaluated the in vivo activity of SS1P and RG7787 in a subcutaneous KLM-1 xenograft model. At the maximum dose that can be given safely QOD (3 x 0.4 mg/kg), SS1P had no effect on tumor growth. RG7787 can be administered at much higher doses because of the lower offtarget toxicity associated with the PE24 moiety (13, 15 ). An exploratory toxicity study in mice indicated that 4 x 4 mg/kg RG7787 QOD iv can be safely administered. We chose to give 3 x 2.5 mg/kg. The first RG7787 cycle of 3 doses induced a small but statistically significant decrease in tumor size. This is in contrast with the high sensitivity to RG7787 of KLM-1 in vitro. To determine if the small response was due to low uptake of RG7787, we quantified RG7787 uptake in KLM-1 tumors by optimizing a previously developed flow cytometry method of dissociated tumor cells (21) . This dissociation process removes bound RITs from the cell surface and allows us to quantify the cells that internalized RG7787. Other methods measure both bound and internalized molecules as well as molecules trapped in the extracellular fluid or by other cell types (20) . We found that a dose of 2.5 mg/kg RG7787 reached only about half of the tumor, suggesting that the small tumor regression is linked to tumor accessibility, rather than RG7787 activity. Further research will focus on the amount of RIT that accumulates in the tumor cells, which is also critical with regards to cytotoxicity.
Paclitaxel dramatically improves RG778 tumor response, but not uptake
The entry of antibodies and antibody-derived therapeutics like RITs into solid tumors is known to be limited by the close packing of tumor cells, high interstitial pressure within tumors, and a lack of functional lymphatics (30) . One approach to overcome this barrier is to combine RITs with chemotherapeutics. Combining SS1P with paclitaxel, e.g., resulted in an enhanced response in A431/H9 xenografts (21) . Similar observations were made with our KLM-1 tumor model. We 
Clinical prospects and challenges for RG7787 in PDAC
PDAC is well known for its dense stroma, which results in poor drug uptake. Compounds that target the stroma have been shown to improve PDAC accessibility for cytotoxic drugs (31) .
Several examples are currently in clinical trials. The combination of gemcitabine with nabpaclitaxel, an albumin-bound formulation of paclitaxel particles, e.g., has recently shown to be an active regimen in PDAC (32) . The evaluation of stroma-targeting compounds in combination with RG7787 will require in vivo models that closely mimic the PDAC microenvironment (31,33).
In conclusion, RG7787 is a novel anti-mesothelin RIT optimized for clinical use with a significant activity in vitro in established and primary PDAC cell lines. RG7787 can be administered safely at high doses in mice, and induces significant tumor responses in a PDAC mouse model. This response is dramatically enhanced when combined with paclitaxel, resulting in durable near-complete regressions. Our pre-clinical findings demonstrate that RG7787 merits further evaluation for the treatment of PDAC. Average data from at least three independent experiments is displayed. Mesothelin expression is evaluated by flow cytometry, and IC 50 s are derived from 72-hr ATP cell viability assays. Cell lines are ranked from most to least sensitive to RG7787. 
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